{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:39:04Z","timestamp":1787017144364,"version":"build-2736575974"},"reference-count":42,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antifibrotic (AF) therapy has been shown to potentially reduce the risk of lung cancer (LC) in patients with idiopathic pulmonary fibrosis (IPF). Our study further assesses the impact of AF use and LC incidence in a real-world cohort with patient-level data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective multisite cohort study involving patients with IPF followed at Mayo Clinic between 2005 and 2022 was conducted. We identified individuals with new diagnoses of LC in the pre-AF and post-AF eras and defined AF use as continuous treatment for 6 months or more before LC diagnosis. Given the inclusion of LC cases prior to the wide availability of AF therapy and potential differences in patients exposed and unexposed to treatment, propensity score analysis with inverse probability of treatment weighting (IPTW) was used to balance comparator groups. Fine and Gray modelling was used to explore risk factors for developing LC, reported as parameter subdistribution HRs (SHR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3313 patients with IPF were included (1161 treated and 2152 non-treated). LC incidence rates were lower for treated patients in the post-AF era (0.34 vs 1.25 per 100 person-years, p&lt;0.001). After IPTW, 2148 treated were compared with 2167 non-treated individuals. AF treatment was independently associated with reduced LC risk (SHR 0.36 (0.16\u20130.82), p=0.02), while smoking history and higher forced vital capacity were associated with increased risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AF use appears to be associated with a reduced incidence rate and risk of LC in patients with IPF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223803","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:55:12Z","timestamp":1769061312000},"page":"672-678","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Antifibrotic therapy and lung cancer risk in patients with idiopathic pulmonary fibrosis: a large retrospective propensity-weighted cohort study"],"prefix":"10.1136","volume":"81","author":[{"given":"Supiya","family":"Kijlertsuphasri","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Division of Pulmonary and Pulmonary Critical Care Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tananchai","family":"Petnak","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3329-5717","authenticated-orcid":false,"given":"Teng","family":"Moua","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"2026061502201451000_81.7.672.1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chest.2020.07.035","article-title":"Impact of Idiopathic Pulmonary Fibrosis on Longitudinal Health-care Utilization in a Community-Based Cohort of Patients","volume":"159","author":"Farrand","year":"2021","journal-title":"Chest"},{"key":"2026061502201451000_81.7.672.2","first-page":"179","article-title":"Idiopathic Pulmonary Fibrosis: Treatment and Prognosis","volume":"9","author":"Fujimoto","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"2026061502201451000_81.7.672.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-018-0899-4","article-title":"Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease \u2013 analysis of institutional and population data","volume":"19","author":"Yoon","year":"2018","journal-title":"Respir Res"},{"key":"2026061502201451000_81.7.672.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2009.01547.x"},{"key":"2026061502201451000_81.7.672.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07494-w","article-title":"Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling","volume":"20","author":"Leng","year":"2020","journal-title":"BMC Cancer"},{"key":"2026061502201451000_81.7.672.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-0905-8","article-title":"Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"19","author":"Yoo","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026061502201451000_81.7.672.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026061502201451000_81.7.672.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2026061502201451000_81.7.672.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-018-0845-5","article-title":"The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis","volume":"19","author":"Guenther","year":"2018","journal-title":"Respir Res"},{"key":"2026061502201451000_81.7.672.10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026061502201451000_81.7.672.11","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-218281"},{"key":"2026061502201451000_81.7.672.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2017.09.007"},{"key":"2026061502201451000_81.7.672.13","unstructured":"Barakat A , Breeze J , LaCamera P . Lung cancer incidence in patients on antifibrotic therapy for idiopathic pulmonary fibrosis. In: D105 ILD EPIDEMIOLOGY II. edn: A7794."},{"key":"2026061502201451000_81.7.672.14","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S129785"},{"key":"2026061502201451000_81.7.672.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.11.010"},{"key":"2026061502201451000_81.7.672.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-10-201205150-00004"},{"key":"2026061502201451000_81.7.672.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200612-1759OC"},{"key":"2026061502201451000_81.7.672.18","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.7.2003140"},{"key":"2026061502201451000_81.7.672.19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/sim.8887","article-title":"Propensity score trimming mitigates bias due to covariate measurement error in inverse probability of treatment weighted analyses: A plasmode simulation","volume":"40","author":"Conover","year":"2021","journal-title":"Stat Med"},{"key":"2026061502201451000_81.7.672.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018174","article-title":"Weight trimming and propensity score weighting","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"key":"2026061502201451000_81.7.672.21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5762"},{"key":"2026061502201451000_81.7.672.22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/sim.7153","article-title":"Goodness-of-fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals","volume":"36","author":"Boher","year":"2017","journal-title":"Stat Med"},{"key":"2026061502201451000_81.7.672.23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5815"},{"key":"2026061502201451000_81.7.672.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82182-8"},{"key":"2026061502201451000_81.7.672.25","doi-asserted-by":"crossref","first-page":"00111","DOI":"10.1183\/23120541.00111-2016","article-title":"Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis","volume":"4","author":"Kato","year":"2018","journal-title":"ERJ Open Res"},{"key":"2026061502201451000_81.7.672.26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0359"},{"key":"2026061502201451000_81.7.672.27","doi-asserted-by":"crossref","unstructured":"Yoon H-Y , Han K-I , Kim H . Pirfenidone and risk of lung cancer development in IPF: a nationwide population-based study. Eur Respir J 2024. doi:10.1183\/13993003.01484-2024","DOI":"10.1183\/13993003.congress-2024.OA4558"},{"key":"2026061502201451000_81.7.672.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.04.114"},{"key":"2026061502201451000_81.7.672.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2017.03.016"},{"key":"2026061502201451000_81.7.672.30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01550","article-title":"The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC","volume":"9","author":"Marwitz","year":"2019","journal-title":"Front Oncol"},{"key":"2026061502201451000_81.7.672.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67904-8","article-title":"Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer","volume":"10","author":"Fujiwara","year":"2020","journal-title":"Sci Rep"},{"key":"2026061502201451000_81.7.672.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2162-z","article-title":"The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts","volume":"16","author":"Mediavilla-Varela","year":"2016","journal-title":"BMC Cancer"},{"key":"2026061502201451000_81.7.672.33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11523-015-0367-8","article-title":"Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology","volume":"10","author":"Dhillon","year":"2015","journal-title":"Target Oncol"},{"key":"2026061502201451000_81.7.672.34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/1759-7714.14333","article-title":"Lung cancer risk prediction models based on pulmonary nodules: A systematic review","volume":"13","author":"Wu","year":"2022","journal-title":"Thorac Cancer"},{"key":"2026061502201451000_81.7.672.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.2168"},{"key":"2026061502201451000_81.7.672.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00590-8"},{"key":"2026061502201451000_81.7.672.37","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-214626"},{"key":"2026061502201451000_81.7.672.38","doi-asserted-by":"crossref","DOI":"10.4172\/2161-1165.1000227","article-title":"Multicollinearity in Regression Analyses Conducted in Epidemiologic Studies","volume":"6","author":"Vatcheva","year":"2016","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2026061502201451000_81.7.672.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.11.017"},{"key":"2026061502201451000_81.7.672.40","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7992"},{"key":"2026061502201451000_81.7.672.41","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/1759-7714.13935","article-title":"Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis","volume":"12","author":"Kai","year":"2021","journal-title":"Thorac Cancer"},{"key":"2026061502201451000_81.7.672.42","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-24-45"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:22:20Z","timestamp":1781515340000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,6,15]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/thorax-2025-223803"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223803","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}